Author: Ravi Shankar

Continued purchases and organic accumulation drive approximately 10% growth in SOL holdings since the Company’s August 12 Earnings Update

Quarter-to-date, SOL has outperformed the Nasdaq-100 by 72%, and DFDV has outperformed SOL by 1.4x over that same period

CHAD brings Digital Credit 2.0 to income investors: a 13% annual dividend rate supported by a productive SOL treasury

BOCA RATON, FL, Sept. 28, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that it has added approximately 47,706 SOL to its treasury since September 21, 2026, bringing total holdings to approximately 2,538,010 SOL and SOL equivalents worth $309M.

The latest increase represents approximately 2% growth week over week, and brings total SOL and SOL equivalents growth to approximately 10% since the Company’s Q2 earnings report on August 12. With the recently established $300 million CHAD ATM providing an additional source of growth capital, the Company believes its SOL accumulation flywheel is continuing to gain momentum.

“We are building our SOL treasury week by week, and those gains are adding up,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “Our SOL and SOL equivalents grew another 2% last week. Since our Q2 earnings update, we have added over 226,000 SOL, expanding our treasury 10% in just six weeks. With tokenization and agentic AI opening new opportunities for Solana, we intend to keep accumulating and put those holdings to work.”

Building for Tokenization and Agentic AI

DFDV believes tokenization and agentic AI represent significant potential drivers of demand for crypto, with Solana well positioned to support financial activity that requires fast settlement, low transaction costs, and around-the-clock availability.

“Tokenization brings stocks, funds, and other financial assets onchain. Agentic AI introduces software that can transact, make payments, and manage resources on its own,” continued Onorati. “Both need financial infrastructure that operates at lightning speed. We believe Solana will become a core part of that infrastructure, and we intend to keep building our position as that opportunity develops.”

From June 30, 2026 through September 25, 2026, SOL gained approximately 73%, outperforming the Nasdaq-100 by approximately 72 percentage points. DFDV shares gained approximately 105% over the same period, delivering approximately 1.4 times SOL’s percentage return.

“This quarter’s performance has been strong, but our investment thesis in Solana extends much further,” said Onorati. “We see a future with trillions of dollars of assets, payments, and economic activity moving onchain, and we believe Solana will capture a meaningful share of that opportunity. Our objective is to accumulate as much SOL as we can ahead of that adoption, put it to work, and compound our holdings as the network grows.”

CHAD: Bringing Digital Credit 2.0 to More Investors
Alongside continued SOL accumulation, DFDV continued expanding its efforts to build awareness, market access, and liquidity for CHAD, its Nasdaq-listed variable-rate preferred stock. CHAD currently carries a 13% annual dividend rate on its $10 stated amount, equivalent to $1.30 per share annually at the current rate, with dividends paid each business day when declared.

The Company views CHAD as Digital Credit 2.0: preferred equity supported by a productive treasury. Through staking and validator operations, DFDV’s SOL holdings generate recurring rewards and fees, providing an organic source of income to support dividend obligations. Additional SOL deployed into these operations can expand the treasury’s earning capacity, connecting continued accumulation with the economics supporting CHAD.

“Digital Credit 2.0 starts with a simple idea: the assets supporting the preferred should themselves be productive,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “Our SOL treasury earns additional SOL through staking and validator operations. That gives CHAD an income-generating foundation and gives us the opportunity to grow that earning power as we accumulate more.”

“CHAD brings that story to income investors through a 13% annual dividend rate and payments each business day when declared,” continued Onorati. “We want to make CHAD a widely recognized name in digital credit. Expanding investor access, demonstrating dividend coverage, and supporting trading toward its $10 stated amount are priorities for us.”

Learn more about CHAD at www.defidevcorp.com/chad.

For more information, visit defidevcorp.com. To stay up to date with the latest developments and insights, subscribe to our blog.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.
The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated issuance price of shares under the ATM program, the intended use of proceeds, and the Company’s ability to expand its SOL treasury and increase revenue, and can be identified by words such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated losses that the Company may incur as a result of a decrease in the market price of SOL; (ii) a failure for the demand for SOL, or activity on the SOL network, to continue to develop and grow as predicted in our DFDV Model or at all; (iii) volatility in our stock price, including due to future issuances of common stock and securities convertible into common stock; (iv) the effect of and uncertainties related to the ongoing volatility in interest rates; (v) our ability to achieve and maintain profitability in the future; (vi) the impact on our business of the regulatory environment and complexities of complying with such environment, including changes in securities laws or other laws or regulations; (vii) changes in the accounting treatment relating to the Company’s SOL holdings; (viii) our ability to respond to general economic conditions; (ix) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (x) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth; and (xi) other risks and uncertainties more fully described in the section captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and other reports we file with the SEC.

As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

• 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need 
• First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME population
• Updated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction

EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The Company also reported 2-year data from the SPECTRA clinical trial.

“The initiation of 4SIGHT marks an important step in advancing 4D-150 toward becoming a continuous backbone therapy for sustained control of major VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. “The favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction observed through two years in the SPECTRA Part 1 clinical trial in DME strengthen our confidence as we expand 4D-150 into the 4SIGHT Phase 3 trial in DME. Following enrollment completion of our two 4FRONT Phase 3 trials in wet AMD, 4SIGHT for DME represents our second Phase 3 program.”

4SIGHT: Phase 3 Trial Design and Regulatory Pathway

4SIGHT is a global Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled trial of intravitreal 4D-150 in treatment-naïve patients with DME (N=514). All patients will receive five aflibercept loading doses. The primary endpoint is non-inferiority in the mean change from baseline in best corrected visual acuity (BCVA) at Week 52. The key secondary endpoints are treatment burden reduction, comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm through Week 52, and the proportion of participants with a ≥2-step improvement from baseline in Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at Week 52. Patients in both arms will be eligible for supplemental aflibercept injections.

Similarly to the 4FRONT Phase 3 wet AMD trials, randomization requires on-trial demonstration of aflibercept responsiveness following the first three of five loading doses during the run-in period (central subfield thickness (CST) ≥10% reduction and ≤400 µm or CST <315 µm).

4D-150 for DME has U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy designation, and the Company has alignment with the FDA and the European Medicines Agency on potential Biologics License Application and marketing authorization application filings with the single 4SIGHT Phase 3 DME trial, based on data generated to date for 4D-150 in both the SPECTRA and PRISM clinical trials combined with data from the two Phase 3 clinical trials in the 4FRONT wet AMD program.

“Having treated patients across multiple retinal gene therapy programs over the past decade, including treating the first human patient with 4D-150 nearly five years ago and now enrolling the first patient in 4SIGHT, I believe the initiation of 4SIGHT represents an important milestone for our field,” said Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates, Clinical Professor at the University of Nevada, Reno School of Medicine, and Chair of the 4DMT Retina Advisory Board. “In real-world practice, many patients with DME struggle to adhere to the frequent anti-VEGF injection schedule because of the substantial treatment burden and the need for numerous other physician visits, which may contribute to suboptimal visual outcomes. Based on the 2-year data from the SPECTRA trial, I believe a single in-office injection of 4D-150 has the potential to transform the treatment paradigm for DME by providing sustained disease control while reducing treatment burden.”

2-Year Results from SPECTRA Clinical Trial (Data Cutoff of March 12, 2026):

• Safety Results (N=22):
  • 4D-150 was well tolerated, with no intraocular inflammation at any timepoint
  • No ocular serious adverse events
  • No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions
  • No progression to proliferative diabetic retinopathy or vitreous hemorrhage
• Clinical Activity Results for Phase 3 Dose (3E10 vg/eye, n=9):
  • Mean gain in BCVA of +10.8 letters
  • Mean reduction in CST of -176 µm, as measured by optical coherence tomography
  • Supplemental Injections:
    • Utilized stringent supplemental criteria to maximize patient safety while assessing initial clinical activity
    • Post-aflibercept loading doses (3), patients required substantially fewer injections compared to on-label aflibercept 2mg Q8W:
      • 61% overall treatment burden reduction (5.2 mean supplemental injections per patient vs. 13.0 injections projected with on-label aflibercept 2 mg Q8W)
      • 75% estimated overall treatment burden reduction utilizing 4SIGHT Phase 3 supplemental injection criteria, which are more in line with contemporary Phase 3 trials (3.2 estimated mean supplemental injections per patient vs. 13.0 injections projected with on-label aflibercept 2 mg Q8W; retrospective estimate, actual results in 4SIGHT may differ)
      • 2 of 9 (22%) remained injection-free

Additional details on the SPECTRA data and 4SIGHT clinical trial design can be found in our corporate deck on our Investor Relations website.

About 4D-150

4D-150 is a potential continuous backbone therapy designed to provide multi-year, and potentially lifelong, sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) within the retina following a single intravitreal injection. 4D-150 utilizes our customized and primate-evolved intravitreal AAV vector (R100), which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform, as well as a proprietary transgene payload designed for robust aflibercept expression plus an anti-VEGF-C inhibitory RNA. 4D-150 is being developed for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which each affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision.

About DME

DME, or diabetic macular edema, is a complication of diabetic retinopathy and is a highly prevalent disease with significant unmet medical need and poor treatment adherence. It is estimated that there are approximately one million individuals with DME in the U.S., according to published data. DME is characterized by inflammation and swelling in the macula due to leakage from blood vessels, which can lead to vision loss. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks, although patient compliance with therapy is poor and results in high unmet medical need.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.  

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, treatment-burden reduction, durability and clinical benefits of, the potential market for, as well as the plans, announcements and related timing for the clinical development, regulatory interactions, and potential commercialization of our product candidates, including 4D-150. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target,” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled “Risk Factors” in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics’ views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Media:
Jenn Gordon
dna Communications
Media@4DMT.com

Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease

Subgroup analyses support CD47 expression as a predictive biomarker

ASPEN-06 clinical findings further validate Company’s biomarker-driven development strategy and reinforce its continued advancement in the ongoing Phase 2 ASPEN-09-Breast clinical trial

On track for mid-2027 topline data readout from 80 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the publication of clinical data from its ASPEN-06 randomized Phase 2 clinical trial in Nature Medicine.

The Nature Medicine publication, titled “Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial” can be accessed here. The data demonstrated that the Company’s investigational CD47-blocker, evorpacept, generated encouraging efficacy with manageable safety among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

“Publication of our ASPEN-06 data in Nature Medicine, a prestigious peer-reviewed scientific journal, further validates the clinical potential of evorpacept and reinforces our biomarker-driven development strategy,” said Barbara Klencke, M.D., Chief Medical Officer of ALX Oncology. “Data from ASPEN-06 demonstrated that patients whose tumors retained HER2 expression and had high CD47 expression experienced the greatest benefit from evorpacept-based therapy, supporting our hypothesis that evorpacept can enhance the activity of HER2-directed treatment regimens and highlights CD47 expression as a potential predictive biomarker. These findings further strengthen our conviction in the ongoing Phase 2 ASPEN-09-Breast clinical trial in HER2-positive metastatic breast cancer, which remains on track for a topline data readout from 80 patients in mid-2027.”

The ASPEN-06 clinical trial (NCT05002127) was a randomized Phase 2 (open-label)/3 (blinded), international, multi-center study, that evaluated evorpacept in combination with HERCEPTIN^® (trastuzumab), CYRAMZA^® (ramucirumab) and paclitaxel (TRP) compared with TRP alone (control), for patients with metastatic second- or third-line HER2 overexpressing GC/GEJ adenocarcinoma who have progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy, and who were suitable for chemotherapy. One hundred twenty-seven adult patients were enrolled in the Phase 2 portion of the study.

Results demonstrated that evorpacept plus TRP achieved an objective response rate (ORR) of 40.3% compared with 26.6% for TRP alone in the intent-to-treat (ITT) population. Among patients with retained HER2-positive disease, based either on a fresh tumor biopsy or ERBB2 gene amplification detected in circulating tumor DNA (ctDNA), ORR increased to 48.9% versus 25.0% for the control arm.

Post-hoc biomarker analyses demonstrated CD47 expression as a potential predictive biomarker for evorpacept. Among patients with retained HER2-positive disease and elevated CD47 expression (≥5% CD47 IHC3+ staining), evorpacept plus TRP achieved an ORR of 63.6% compared with 23.1% for TRP alone, with improvements in median progression-free survival (PFS) to 19.5 months versus 7.0 months and median duration of response (DOR) of 25.5 versus 8.4 months, supporting further evaluation of CD47-guided patient selection in future studies.

In conclusion, findings from the randomized Phase 2 portion of the ASPEN-06 study suggest that evorpacept in combination with TRP may provide meaningful clinical benefit as a second- or third-line treatment for patients with GC or GEJ cancer with retained HER2 expression. Post-hoc analyses further suggest that this benefit may be enhanced in patients with high CD47 expression, supporting the proposed mechanism that both retained HER2 expression and elevated CD47 levels may be important drivers of efficacy through enhanced antibody-dependent cellular phagocytosis. Given the Company’s disciplined focus and resource allocation priorities, ALX Oncology elected to not pursue a U.S. registrational path with a Phase 3 trial in GC and will consider exploring development partnerships to advance this program in gastric cancer. Importantly, findings from the ASPEN-06 study further validate the Company’s biomarker-driven development approach and support the ongoing Phase 2 ASPEN-09-Breast trial (NCT07007559) evaluating evorpacept in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic breast cancer, with topline data from 80 patients expected in mid-2027.

HERCEPTIN^® and CYRAMZA^® are the registered trademarks of their respective owners.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, such as the ongoing Phase 2 ASPEN-09-Breast clinical trial in HER2-positive metastatic breast cancer, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Relations Contact:
Kevin Lui
Director, Investor Relations
kevin.lui@precisionaq.com

Media Contact:
Genevieve Britton
Senior Director, Public Relations
genevieve.britton@precisionaq.com

Company holds exclusive access to imaging data from 2,100+ U.S. hospitals through its ongoing data partnership with vRad, the largest teleradiology provider in the United States

BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — GuideAI Health Corp. (Cboe CA: GDAI) (FSE: ZN0) (“GuideAI” or the “Company“) is pleased to announce the renewal of its data exclusivity agreement with vRad (Virtual Radiologic), which aims to develop artificial intelligence models for the detection and characterization of multiple vascular diseases. The renewed collaboration provides GuideAI with exclusive access to imaging data from more than 2,100 hospitals across the United States, which the Company believes to be one of the largest and most diverse real-world imaging datasets of its kind.

Under the renewed partnership, GuideAI retains exclusive rights to develop AI models using de-identified imaging data generated across vRad’s national network of more than 2,100 hospitals and healthcare facilities. GuideAI’s technology is currently deployed within the workflow of vRad’s approximately 500 radiologists, where it supports the identification of vascular disease at the point of care.

The scale and diversity of vRad’s dataset provide GuideAI with a durable foundation on which to train and validate its algorithms. Building on its work in peripheral arterial disease, the Company intends to expand its platform to the detection and characterization of multiple vascular diseases, with the goal of surfacing disease earlier and supporting more precise, more comprehensive treatment decisions for patients nationwide.

GuideAI Health CEO, Raj Shah, commented, “Renewing our exclusive data collaboration with vRad is a defining moment for GuideAI. Access to imaging data from more than 2,100 hospitals, combined with the trust of the 500 radiologists who already have access to our technology in their daily workflow, gives us an exceptional foundation to build clinically meaningful AI, furthering our aim of helping clinicians catch disease earlier and improve outcomes for patients.”

About GuideAI Health Corp.

GuideAI Health Corp. is a healthcare technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease. By surfacing disease earlier, GuideAI aims to improve patient outcomes while helping hospitals and radiology groups deliver more comprehensive vascular care.

For more information, please visit www.guideaihealth.com.

On Behalf of the Board of Directors:

Raj Shah

CEO

Contact:

Phone: (416) 309-3583
Email: info@guideaihealth.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking information”). Forward-looking information in this news release includes, but is not limited to, statements regarding: the continuation and anticipated benefits of the Company’s renewed data exclusivity agreement and collaboration with vRad; the Company’s continued exclusive access to, and ability to use, de-identified imaging data generated across vRad’s network; the scope, scale, diversity and anticipated value of that dataset; the continued deployment and use of GuideAI’s technology within vRad’s radiology workflow; the Company’s ability to train, develop, validate and commercialize artificial intelligence models for the detection and characterization of vascular diseases; the expansion of the Company’s platform beyond peripheral arterial disease; the potential for the Company’s technology to identify disease earlier, support more precise and comprehensive treatment decisions and improve patient outcomes; and the Company’s business plans, objectives and future activities. Forward-looking information is often, but not always, identified by words or phrases such as “anticipates”, “believes”, “expects”, “intends”, “plans”, “aims”, “goal”, “may”, “will”, “would”, “could”, “should”, “potential”, “continue” and similar expressions. 

Forward-looking information is based on management’s estimates, assumptions and expectations as of the date of this news release, including assumptions regarding: the continued validity and enforceability of, and performance by the parties under, the renewed agreement; the Company’s continued ability to access and lawfully use sufficient quantities of de-identified imaging data; the quality, completeness, diversity and representativeness of the available data; the continued availability, performance and integration of the Company’s technology within vRad’s workflow; the Company’s ability to retain qualified personnel, secure required financing and other resources, protect its intellectual property and data rights, and complete development, testing and validation activities; and the receipt of any required regulatory, clinical, commercial or third-party approvals. Although the Company considers these assumptions reasonable, they may prove to be incorrect. 

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied, including risks relating to: the termination, non-renewal, amendment, breach or unenforceability of the renewed agreement; interruptions, restrictions or loss of access to imaging data or the vRad network; limitations in the quantity, quality, completeness, diversity or representativeness of available data; privacy, data protection, cybersecurity, data de-identification, consent and regulatory compliance; the accuracy, reliability, generalizability, validation and clinical utility of artificial intelligence models; development delays, technical failures, integration challenges and the inability to achieve expected performance or commercial objectives; changes in laws, regulations, standards of care or regulatory requirements applicable to artificial intelligence, medical devices, healthcare or data use; failure to obtain or maintain required approvals; intellectual property disputes and the inability to protect proprietary rights; competition and technological change; dependence on key personnel, collaborators, service providers and third parties; the availability of capital and other resources; and the possibility that the anticipated clinical, operational or commercial benefits of the collaboration and the Company’s technology will not be realized. Additional risks are described in the Company’s public disclosure documents available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Jacopo Barontini and Fulvio Taglialatela Strengthen Support for Italian Companies and Creditors Facing Complex Restructuring, Turnaround and Cross-Border Challenges

MILAN, Sept. 28, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Jacopo Barontini as a Senior Managing Director and Head of Turnaround & Restructuring in Italy, joined by Fulvio Taglialatela as a Managing Director, both in the firm’s Corporate Finance segment in Milan. They will support companies and creditors through complex domestic and cross-border restructuring and turnaround situations.

“Businesses and capital providers in Italy face growing financial and operational pressures due to higher costs, subdued growth and continued economic uncertainty,” said Emanuele Grasso, Italy Leader and Head of Italy Corporate Finance at FTI Consulting. “Jacopo and Fulvio bring deep experience advising clients through critical situations and developing solutions that preserve value. Their arrival reflects our ongoing investment in our capabilities and significantly strengthens our ability to support the restructuring needs of businesses and creditors, from stabilising operations and liquidity to negotiating capital structures and delivering sustainable turnarounds.”

Mr. Barontini brings more than 30 years of experience in restructuring, corporate finance, distressed M&A and special situations, with a focus on financial restructurings, performance improvement and turnaround management. He has advised companies, creditors and investors on domestic and cross-border, in-court and out-of-court matters across a broad range of industries. Mr. Barontini is also a qualified Italian chartered accountant.

Prior to joining FTI Consulting, Mr. Barontini was Head of Financial Restructuring and Co-Head of Financial & Operational Restructuring in Italy at Alvarez & Marsal. He was previously a Partner at Deloitte.

Mr. Taglialatela has more than 20 years of experience in financial restructuring, turnaround and debt restructuring advisory for clients in the real estate, hospitality, consumer products, automotive and energy sectors. He has advised companies, creditors and investors on restructuring transactions, business reviews, debt advisory matters and turnaround situations. Mr. Taglialatela is also a qualified Italian chartered accountant and auditor. Before joining FTI Consulting, Mr. Taglialatela was a Senior Director at Alvarez & Marsal. He previously worked at Deloitte and PwC.

Diederick van der Plas, EMEA Co-Chair and EMEA Head of the Corporate Finance segment at FTI Consulting, added, “Jacopo and Fulvio are well established in Italy’s restructuring market, with strong relationships across the country’s business and financial community. Their arrival strengthens our ability to take on larger and more complex mandates in Italy, as well as cross-border engagements when clients’ needs extend beyond the domestic market. We look forward to building on these appointments to establish FTI Consulting as a leading restructuring adviser in Italy, giving clients access to the full strength of our global practice.”

Commenting on his appointment, Jacopo Barontini said, “FTI Consulting’s independence, collaborative culture and dedicated global restructuring and distress-related capabilities were key to my decision to join. I look forward to building the team in Italy with Fulvio and colleagues who share my commitment to helping clients achieve the best possible outcomes in stressed and distressed situations.”

Mr. Taglialatela added, “Companies facing financial distress need practical advice, decisive action and solutions that deliver tangible results. That approach has guided my work throughout my career. FTI Consulting’s global restructuring capabilities provide a strong platform to apply that approach, and I am excited to work with Jacopo to grow the practice in Italy.”

The appointments of Mr. Barontini and Mr. Taglialatela follow the recent addition of Dr. Riccardo Siliprandi in the Milan office to lead FTI Consulting’s Energy practice in Italy.

FTI Consulting’s Restructuring team in Italy works with companies, boards, investors, lenders and other stakeholders facing financial or operational pressure. It helps clients improve performance and cash flow, assess the state of a business, manage insolvency proceedings and execute turnaround plans.

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organisations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalised and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.
200 Aldersgate
Aldersgate Street
London, EC1A 4HD

Investor Contact:                                
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com

Media Contact:                                
publicrelations@fticonsulting.com

CINCINNATI, Sept. 28, 2026 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, will announce its Third Quarter 2026 earnings results on Monday, October 26, 2026, after the market closes. PECO’s earnings release and financial supplement will be posted on the Investor Relations section of the Company’s website at https://investors.phillipsedison.com/. Chairman and Chief Executive Officer Jeff Edison, President Bob Myers and Chief Financial Officer John Caulfield will host an earnings conference call, which will also be webcast, on Tuesday, October 27, 2026, at 12:00 p.m. ET.

Third Quarter 2026 Earnings Conference Call and Webcast Details:

• Date: Tuesday, October 27, 2026
• Time: 12:00 p.m. Eastern Time
• Participant Toll-Free Dial-In Number: (800) 715-9871
• Participant Toll Dial-In Number: (646) 307-1963
• Conference ID: 4551083
• Webcast: Third Quarter 2026 Webcast Link

A webcast replay will be available approximately one hour after the conclusion of the event using the same link. Webcasts are archived on PECO’s Investor Relations website.

Connect with PECO
For additional information, please visit https://www.phillipsedison.com/
Follow PECO on:
X at https://x.com/PhillipsEdison
LinkedIn at https://www.linkedin.com/company/phillipsedison&company

About Phillips Edison & Company
Phillips Edison & Company, Inc. (“PECO”) is one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers. Founded in 1991, PECO has generated strong results through its vertically-integrated operating platform and national footprint of well-occupied shopping centers. PECO’s centers feature a mix of national and regional retailers providing necessity-based goods and services in fundamentally strong markets throughout the United States. PECO’s top grocery anchors include Kroger, Publix, Albertsons and Ahold Delhaize. As of June 30, 2026, PECO managed 330 shopping centers, including 302 wholly-owned centers comprising 33.9 million square feet across 31 states and 28 shopping centers owned in three institutional joint ventures. PECO is focused on creating great grocery-anchored shopping experiences and improving communities, one neighborhood shopping center at a time.

PECO uses, and intends to continue to use, its Investors website, which can be found at https://investors.phillipsedison.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. 

Investors:
Kimberly Green, Head of Investor Relations
(513) 692-3399, kgreen@phillipsedison.com

Newtek Advantage® Integrates Banking, Payments, Payroll and Business Information into a More Connected Customer Experience

BOCA RATON, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) — NewtekOne, Inc. (NASDAQ: NEWT) (“NewtekOne” or the “Company”) announced today that its bank subsidiary, Newtek Bank, N.A. (“Newtek Bank”), has expanded connectivity between Newtek Bank accounts and the accounting and business applications independent business owners rely on to manage their businesses. Newtek Bank now integrates with Sage, Xero, FreshBooks, Restaurant365 and other leading applications, building on its existing connectivity with QuickBooks and broadening the digital ecosystem available through Newtek Advantage^®.

This expanded connectivity is designed to make business banking integrated with the systems customers already use to track financial performance, reconcile transactions and manage day-to-day operations. By connecting with QuickBooks, Sage, Xero and FreshBooks, Newtek Bank can integrate with accounting platforms representing approximately 85% of the U.S. small-business accounting software market. Additional supported applications include 1-800Accountant, Expensify, AppFolio, BILL and others.

Newtek Advantage^®, the Company’s internally developed and patent-pending online business portal, serves as the central customer experience for Newtek Bank and NewtekOne’s broader suite of business solutions. Through Newtek Advantage^®, independent business owners can access their Newtek Bank relationship, view banking information, monitor real-time payment activity and connect more of their financial data in a single portal.

The enhanced application connectivity complements NewtekOne’s integrated approach to business financial services. Customers using Newtek Real-Time Payment Solutions can accept credit card, debit card and ACH payments, with merchant processing proceeds settling directly into their Newtek Bank account the same day, seven days a week, 365 days a year. Customers using Newtek Payroll have the ability to fund and execute payroll the same day. Together, these capabilities help connect transactional banking, payments and payroll information with many of the accounting and business applications customers use to operate their businesses.

Barry Sloane, Chairman, President and Chief Executive Officer of NewtekOne, commented, “Independent business owners increasingly expect their bank to work inside the digital systems they use to run their businesses. By expanding Newtek Bank’s connectivity with QuickBooks, Sage, Xero, FreshBooks, Restaurant365 and other applications, we are making banking information more connected to our customers’ daily workflows.”

“The Newtek Advantage^® brings more of the customer relationship into one connected experience. Business owners can access banking information, view real-time payment activity, settle merchant processing proceeds directly into Newtek Bank, fund and execute payroll the same day and connect all of that information with the accounting and business applications they already use. We believe this is an important step in advancing connected business banking for independent business owners.”

“These capabilities also complement Newtek Zero-Fee Business Banking™, which is truly a ‘no fee’ bank account — no monthly service fees, no transaction fees, no ACH fees, no wire fees, no overdraft fees and no minimum balance requirement — that also pays a competitive rate of interest on checking balances.”

Mr. Sloane concluded, “We have built a differentiated, technology-enabled financial services ecosystem that helps independent business owners grow revenue, reduce expense, and reduce risk.”

About NewtekOne, Inc.

NewtekOne^®, Your Business Solutions Company^®, is a financial holding company, which along with its bank and non-bank consolidated subsidiaries (collectively, “NewtekOne”), provides a wide range of business and financial solutions under the Newtek^® brand to independent business owners. Since 1999, NewtekOne has provided state-of-the-art, cost-efficient products and services and efficient business strategies to independent business owners across all 50 states to help them grow their sales, control their expenses, and reduce their risk.

NewtekOne’s and its subsidiaries’ business and financial solutions include: Banking (Newtek Bank, N.A.), Business Lending, SBA Lending Solutions, Electronic Payment Processing, Accounts Receivable Financing & Inventory Financing, Insurance Solutions and Payroll and Benefits Solutions. In addition, NewtekOne offers its clients the Technology Solutions (Cloud Computing, Data Backup, Storage and Retrieval, IT Consulting and Web Services) provided by Intelligent Protection Management Corp. (IPM.com)

Newtek^®, NewtekOne^®, Newtek Bank^®, National Association, Your Business Solutions Company^®, One Solution for All Your Business Needs^® and Newtek Advantage® are registered trademarks of NewtekOne, Inc.

Note Regarding Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the rules and regulations of the Private Securities Litigation Reform Act of 1995 and are based on the current beliefs and expectations of NewtekOne’s management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. See “Note Regarding Forward-Looking Statements” and the sections entitled “Risk Factors” in our filings with the Securities and Exchange Commission, which are available on NewtekOne’s website (https://investor.newtekbusinessservices.com/sec-filings) and on the Securities and Exchange Commission’s website (www.sec.gov). Any forward-looking statements made by or on behalf of NewtekOne speak only as of the date they are made, and NewtekOne does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

SOURCE: NewtekOne, Inc.

Investor Relations & Public Relations
Contact: Bryce Rowe
Telephone: (212) 273-8292 / browe@newtekone.com

Following successful FDA Pre-IND meeting, NewcelX advances IND-enabling activities for NCEL-101

ZURICH, Sept. 28, 2026 (GLOBE NEWSWIRE) — NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine company developing stem-cell-derived therapies for Type 1 Diabetes (T1D), today announced that members of its senior management team will attend the Breakthrough T1D Clinical & Research Congress, taking place October 9–11, 2026, in Philadelphia, Pennsylvania.

During the congress, NewcelX management will be available to meet with researchers, clinicians, investors and potential strategic partners to discuss the Company’s lead program, NCEL-101, and preparations for its planned Phase 1/2a clinical trial in T1D.

The Company’s attendance follows its successful Type B Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA), announced in July 2026. The meeting provided constructive FDA feedback and alignment on the proposed development strategy, including chemistry, manufacturing and controls (CMC) and the preclinical program, and clarified the regulatory pathway toward clinical development of NCEL-101.

Following the Pre-IND meeting, NewcelX has a clear path forward on the remaining IND-enabling work required to support its planned Investigational New Drug (IND) submission. The Company is advancing the necessary preclinical, manufacturing and regulatory activities in preparation for its planned Phase 1/2a clinical trial, subject to applicable regulatory requirements.

NCEL-101 combines NewcelX’s enriched stem-cell-derived pancreatic islet cells with Eledon Pharmaceuticals’ investigational anti-CD40L antibody, tegoprubart, as part of a proposed immunomodulatory regimen intended to support transplanted cell survival and function.

Researchers, investors and potential strategic partners interested in learning more about NCEL-101 and the Company’s planned clinical development program are encouraged to contact NewcelX to arrange a meeting at InvestorRelations@newcelx.com

About NewcelX

NewcelX Ltd. (Nasdaq: NCEL) is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the Company’s lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.

Social Media: LinkedIn, Facebook, X, Instagram

Website: www.newcelx.com

Forward-Looking Statements

This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses its anticipated participation in the Breakthrough T1D Clinical & Research Congress; the expected presentation of NCEL-101 development updates; the potential therapeutic benefits, safety profile, scalability and clinical utility of NCEL-101; the planned development of NCEL-101 in combination with tegoprubart; the advancement and timing of preclinical, manufacturing, regulatory and IND-enabling activities; the planned submission of an Investigational New Drug application; the planned initiation, timing, design and objectives of future clinical trials; the ability of NCEL-101 to support functional insulin production, achieve durable graft survival and function, or provide outcomes comparable to donor islet transplantation; and the Company’s future development plans, strategy, regulatory progress and growth opportunities. These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the regulatory pathways that we may elect to utilize in seeking European Medicines Agency, or EMA, the U.S. Food and Drug Administration, or FDA, and other regulatory approvals; our ability to drive revenue growth, enhance research and development capabilities, and improve financial performance is subject to uncertainties; that our financial position raises substantial doubt about our ability to continue as a going concern; our ability to maintain listing and effectively comply with the listing requirements of the Nasdaq; changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials, including our expectations regarding the timing of commencing further clinical trials, the process entailed in conducting each such trial, including dosages, and the order of such trials with each of our product candidates or whether such trials will be conducted at all; competitive companies, technologies and our industry; the development and commercialization, if any, of any other product candidates that we may seek to develop; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; our ability to establish and maintain strategic partnerships and other corporate collaborations; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; delays in developing or introducing new technologies, products, or applications; competitive pressures that could reduce market share or pricing; the overall global political and economic environment in the countries in which we operate; and security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”) and available at www.sec.gov, as well as in subsequent filings made by NewcelX.

Investor Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
NewCelX@kcsa.com

Company Contact
Sarah Bazak
InvestorRelations@newcelx.com

CALGARY, Alberta, Sept. 28, 2026 (GLOBE NEWSWIRE) — Reconnaissance Energy Africa Ltd. (the “Company”, “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) (NSX: REC), is pleased to provide an update on the Company’s portfolio of assets, including flow test sample results and flow testing operations on the Kavango West 1X Sidetrack (“KW1X”) discovery well in Namibia. Additionally, ReconAfrica announces encouraging results from the soil sampling program conducted in Angola during the second quarter and continued progress of the seismic reprocessing program at Ngulu, offshore Gabon.

Highlights

• Thermogenic gas with a liquid-capable system identified: Flow test samples from the KW1X vertical test indicate thermogenic gas with maturity ranging from late oil to early gas.
• KW1X operations resumed: The Jarvie-1 rig has returned to work.
• Horizontal drilling as early as October: All regulatory amendments have been submitted. Subject to approval, drilling of the horizontal wellbore could begin in October, with flow testing to immediately follow.
• Angola petroleum system: Soil analysis on the MOU acreage suggests an active petroleum system similar to the plays on PEL 73 in Namibia.
• Gabon reprocessing on track: 3D seismic reprocessing at Ngulu is expected to be complete by year-end, concurrently a resource report will be conducted.

KW1X IsoTube Test Results

Flow test samples from the Huttenberg and Elandshoek formations in the KW1X well indicate that the natural gas collected in the samples are thermogenic with liquid potential and have maturities ranging from late oil to early gas.  The upcoming horizontal test is intended to establish sustained flow rates from which additional samples will be obtained to determine liquid composition and to measure liquid yields from the gas stream. 

KW1X Operations Update

In Namibia, a horizontal well will be drilled at KW1X in accordance with the continuing exploration of the Damara Fold Belt. The objectives of this horizontal well flow test are to determine deliverability of the well bore, the liquid yield from the gas stream and formation pressure response.

Required equipment has been procured and is on site or in transit. Rig maintenance is complete, and all permits have been filed with appropriate regulatory bodies for ongoing operations. The Jarvie-1 rig resumed operations and work in the vertical well bore has begun with the removal of the casing, followed by the setting of the whipstock at approximately 2,500 metres before commencement of the horizontal drilling.

Pending approvals and equipment arrival, horizontal drilling will take place in October and is scheduled to take approximately one month. The current design targets a horizontal wellbore of up to 1,000 metres to optimally intersect natural fractures across the Kavango structure. The well will be completed “open hole”, without casing or cement, to maximize flow rate from the fractures and identified porosity zones. Flow testing will occur immediately following the well completion and will be tested prior to acid wash.  

Angola

Preliminary results from the soil sampling program conducted on the MOU acreage in Angola during May and June suggests there is a working petroleum system that is thermogenic with liquid content potential, similar to the Namibian side of the play. Micro seeps at surface suggest vertical migration from deep hydrocarbon accumulations. The next phase of operations will be to shoot a 2D seismic program, possibly in 2027, to outline the structural trend of the Damara Fold Belt.

Gabon

The 3D seismic reprocessing program is utilizing the most current state-of-the art reprocessing technology.   This includes Full Waveform Inversion to help illuminate oil bearing reservoirs within the Loba field and the vast salt related exploration inventory on the concession. The reprocessing project is expected to be completed before year end, concurrently a resource report will be commissioned and appraisal well locations to the Loba oil discovery will be selected. Well planning has commenced for an anticipated spud.

Brian Reinsborough, President and CEO, commented: “We are excited to be moving forward with the open hole horizontal flow test at KW1X following successfully identifying the zone of interest in the upper Huttenberg formation. Measuring a flow rate and determining liquids content at KW1X are essential for moving towards a Final Investment Decision at the Kavango discovery and will provide valuable knowledge on the potential of 22 structures already mapped on our exploration license in Namibia. We look forward to working with our partners to progress this exciting play opening discovery.”

About ReconAfrica

ReconAfrica is a Canadian oil and gas company engaged in the exploration of the Damara Fold Belt and Kavango Rift Basin in the Kalahari Desert of northeastern Namibia, southeastern Angola and northwestern Botswana, where the Company holds petroleum licences and access to ~13 million contiguous acres. The Company also operates the Ngulu block in the shallow waters offshore central Gabon covering 1,214 Km² (equivalent to 54 Gulf of Mexico blocks) which is strategically located near producing oil fields and infrastructure. The Ngulu block includes the Loba oil field discovery and a large inventory of high impact prospects in the pre-salt and post-salt plays. In all aspects of its operations, ReconAfrica is committed to minimal disturbance of habitat in line with international standards and implementing environmental and social best practices in its project areas.

For further information contact:
Brian Reinsborough, President & Chief Executive Officer
Mark Friesen, Vice President, Investor Relations & Capital Markets

IR Inquiries Email: investors@reconafrica.com
Media Inquiries Email: media@reconafrica.com
Tel: +1-877-631-1160

Cautionary Note Regarding Forward-Looking Statements:

Certain statements contained in this press release constitute forward-looking information under applicable Canadian, United States and other applicable securities laws, rules and regulations, including, without limitation, statements with respect to progress of the KW1X well test, well results including any shows and/or indications of hydrocarbons, timing of well tests, duration and completion of the horizontal well test, the ability to source adequately materials needed for the well test in a timely manner, results from production testing, net pay and net reservoir calculations, extent of natural fractures, success case scenarios, side track operations, if any, well capability, composition of hydrocarbons, timing and results of compositional analysis, the extent of horizontal lateral drilling, timing of permits, further appraisal activities, efficiency and economics and the Company’s commitment to minimal disturbance of habitat, in line with best international standards and its implementation of environmental and social best practices in its project areas. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on ReconAfrica’s current belief or assumptions as to the outcome and timing of such future events. There can be no assurance that such statements will prove to be accurate, as the Company’s actual results and future events could differ materially from those anticipated in these forward-looking statements as a result of the factors discussed in the “Risk Factors” section in the Company’s annual information form (“AIF”) dated April 14, 2026, for the financial period ended December 31, 2025, available under the Company’s profile at www.sedarplus.ca. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to ReconAfrica. The forward-looking information contained in this release is made as of the date hereof and ReconAfrica undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Eight-year DOJ contract establishes strategic beachhead for ROC Evidence

Validates ROC’s expanded digital evidence platform and the strategic value of its ZTC acquisition

DENVER, CO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Rank One Computing Corporation d/b/a ROC, (Nasdaq: ROC) (“ROC” or the “Company”), a U.S. leader in Vision AI, building unified biometric, video analytics, and digital evidence solutions, today announces that it has been awarded an eight-year contract with the United States Department of Justice (DOJ) at a total contract value of $64.3 million. Under the contract, ROC Evidence will support the DOJ’s Digital Evidence Review Platform (DERP) program, with review, analysis, and production of digital evidence for federal prosecutions.

“We are honored that the DOJ has selected ROC Evidence for this significant competitive win and consequential beachhead contract for ROC,” said ROC CEO B. Scott Swann. “This award signals trust and validation for our product, demonstrates our ability to execute on long-term federal programs, and leaves ROC well-positioned to capture additional government opportunities with durable, high-margin revenue.”

This eight-year DOJ contract has a total value of $64.3 million, including a committed one-year base period valued at approximately $7 million. The contract also includes seven one-year option periods, which, if exercised at the DOJ’s sole discretion and subject to the availability of appropriations, would generate ongoing revenue for ROC. Under the contract, ROC will develop and support DERP, enabling the ingestion, review, analysis, and production of e-discovery content, including cellphone and social media data, in support of federal prosecutions.

“This win builds on the momentum from our recent federal ABIS award, ROC’s first win of a strategic beachhead customer, and represents another important step for ROC’s competitive technologies that are gaining adoption across the federal market,” added Swann. “From biometric identification to digital evidence, America’s agencies need American-made technology that can perform at scale, support real-world workflows, and break down siloed systems, data sources, and teams.”

The award also reinforces the strategic value of ROC’s acquisition of ZTC, bringing together teams that have worked alongside one another for many years with decades of operational experience supporting consequential investigations and events. ZTC’s digital forensics technology and more than two decades of federal experience expand ROC Evidence’s capabilities for large-scale data ingestion, processing, and analysis, strengthening ROC’s ability to support major federal and national security programs at scale.

About ROC

ROC is a leading U.S. developer and manufacturer of Vision AI, delivering sovereign biometrics, video analytics, and digital evidence through a unified platform. This enables agency and integrator partners to unlock faster, more accurate, and cost-efficient capabilities. At its core, ROC transforms raw pixels into real-time operational awareness for defense, public safety, and digital commerce. The Company is headquartered in Denver, Colo., with additional hubs in Grand Rapids, Mich., and Morgantown, W.V. For more information, please visit the Company’s website: www.roc.ai.

Forward-Looking Statements

This Press Release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” and similar expressions that predict or indicate future events or trends or that are not statements of historical fact. Among other things, the description of the obtained contract in this announcement contains forward-looking statements. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: (i) the U.S. Government’s right to terminate or decline to renew the contract, in whole or in part, at its convenience; (ii) the fact that only the base period is presently funded and that exercise of any option period is at the Government’s sole discretion and subject to the availability of appropriations, such that the full $64.3 million total contract value may not be realized; (iii) risks relating to the Company’s performance under, and its ability to satisfy the technical, delivery, and staffing requirements of, the contract; (iv) changes in government budgets, funding levels, spending priorities, and procurement policies; (v) risks relating to the integration of the ZTC acquisition and the realization of its anticipated benefits; and (vi) the Company’s goals, strategies, future business development, financial condition, and results of operations. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Media inquiries:
Matt Aitken, VP of Marketing
media@roc.ai 

Investor inquiries:
CORE IR
ir@roc.ai